MET and non-small cell lung carcinoma: Finally, the GEOMETRY-E trial is evaluating the anticancer activity of capmatinib in combination with osimertinib compared to platinum-pemetrexed-based doublet chemotherapy as second-line treatment in patients with NSCLC EGFRm, T790M negative, MET amplified who progressed following EGFR TKIs (NCT04816214).